Thymosin Alpha-1 vs MOTS-c Side-Effect Profile Head-to-Head
HealthRX.com
Thymosin alpha-1 has human safety data; MOTS-c has none
Key numbers
- 1,349 adultsAdults with chronic hepatitis B in the 2026 Cochrane review of thymosin alpha-1 trialsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- risk ratio 0.72Risk ratio for serious adverse events with thymosin alpha-1 versus comparison treatments (low certainty)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1.6 mgDose of the Italian Zadaxin schedule, given subcutaneously or intramuscularly twice weeklySource: fda.gov, as cited Nov 7, 2026
- 17 million dosesZadaxin doses given after marketing, per manufacturer-linked authors (not independent review)Source: fda.gov, as cited Nov 7, 2026
At a glance
- Drug A / Thymosin alpha-1 (thymalfasin), 28-amino-acid immune-modulating peptide [3]
- Drug B / MOTS-c, 16-amino-acid peptide encoded in mitochondrial DNA [2]
- FDA approval / Neither is FDA-approved [3][2]
- Human safety data, Drug A / Hepatitis B trial data plus manufacturer-linked postmarketing reports; zero FDA adverse-event reports as of April 22, 2024 [3][1]
- Human safety data, Drug B / None; the stated injection concern is immunogenicity [2][4]
- Label cautions, Drug A / Italian Zadaxin label: contraindicated in pregnancy and breastfeeding; caution with allergy, autoimmune disease and other immune-modulating drugs [3]
- Sport / MOTS-c is prohibited at all times by WADA; thymosin alpha-1 is not named [5]
Is there a head-to-head side-effect comparison?
No. Because no human study of MOTS-c exists [2], no trial can have compared it with thymosin alpha-1. What follows sets thymosin alpha-1's human safety data against FDA's stated concerns about MOTS-c.
Questions worth asking
What each peptide is
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract. Thymalfasin is the synthetic version with the same sequence, and Zadaxin is the brand of the finished injection sold outside the US at 1.6 mg per vial; that finished product is not interchangeable with bulk thymosin alpha-1 powder [3]. It is described as an immune modulator that augments T-cell function [6].
MOTS-c, short for mitochondrial open reading frame of the 12S rRNA-c, is a 16-amino-acid peptide of about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 [2][7]. Its pharmacology comes from cells and rodents: it inhibits the folate cycle, activates AMPK and, in mice, prevented diet-induced obesity and age-dependent insulin resistance [7].
Thymosin alpha-1: what the human safety data show
The 2026 Cochrane review
A 2026 Cochrane review pooled 10 randomized trials of thymosin alpha-1 in 1,349 adults with chronic hepatitis B, published between 1991 and 2018 and run in Bangladesh, China, Italy, Korea, Singapore and Taiwan [1]. For harms, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [1]. On benefit, the review found possibly lower all-cause mortality but with very low certainty, and the reviewers said they were not sure thymosin alpha-1 helps [1].
Postmarketing reports and the adverse-event database
Authors tied to the manufacturer report that more than 4,400 people were enrolled in trials and more than 17 million doses of Zadaxin were given after marketing, with adverse experiences described as infrequent and mild; that is company-linked data, not an independent review [3]. FDA's search of its adverse-event database on April 22, 2024 retrieved zero reports for thymosin alpha-1 [3].
What the Italian Zadaxin label says
According to FDA's review, the Italian Zadaxin label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and when it is used with other immune-modulating drugs [3]. The Italian schedule is 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, repeated from week 8 to week 12 at the second vaccination [3]. There is no US-approved dose [3].
MOTS-c: what is known about its safety
FDA found no human exposure data on MOTS-c by any route of administration, no animal toxicity studies and no immunogenicity data, and its adverse-event database search through March 9, 2025 retrieved no MOTS-c reports [2]. The concern FDA states for injection is immunogenicity, an immune reaction to the peptide, from aggregation and peptide-related impurities [2][4]. There are no pharmacokinetic data in humans or in live animals; the one kinetic observation is that MOTS-c breaks down quickly in human blood in vitro, which raises the question of whether injecting it can produce active levels [2].
The products nominated to FDA were 5 mg and 10 mg subcutaneous injections for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity [2]. Those are proposed products, not a tested dose [2].
The human studies that do exist measured the body's own MOTS-c, and nobody was given the peptide. In a randomized trial of 30 healthy adults, plasma MOTS-c showed only a trend to rise after endurance exercise and was not related to fitness [9].
In mice, injected MOTS-c at 0.5 mg/kg/day intraperitoneally produced about 20% lower body weight after 8 weeks on a high-fat diet, and 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [2][10]. FDA noted that the molecular targets are unknown and that no dose-response relationships were assessed [2]. Rodent doses cannot be converted into human doses.
Regulatory status
Thymosin alpha-1 is not FDA-approved; four US orphan drug designations are a separate process and not approvals [3]. FDA lists national approvals in Italy (adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication) and Hong Kong. Two older reviews by authors tied to the developer say it is approved in over 35 countries (2009) and more than 30 countries (2007); FDA could not independently verify those broader claims [3][11][12].
On compounding, FDA's safety-risk page carries thymosin alpha-1 in its nominated-but-withdrawn table: it had been in the significant-risk category and came off when the nominators withdrew. FDA's stated concerns remain, including a significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information inadequate to understand the extent of any safety issues [4]. In December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [13]. Thymosin alpha-1 is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [14].
For MOTS-c, FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the pharmacy bulks list, citing no human safety or effectiveness data, no animal toxicity studies, poor characterization, and existing FDA-approved treatments for two of the nominated uses [2]. The advisory committee voted in favor of adding it on July 23, 2026, against the staff recommendation; that is advice only, not binding, and MOTS-c is not on the list [15][16]. HHS's October 2026 draft policy names MOTS-c among six peptides. It covers MOTS-c acetate by subcutaneous or intramuscular injection and says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met. It is a draft, not binding and not an approval [16][14]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [16].
Sport: WADA's Prohibited List names MOTS-c in S4.4.1 as an AMPK activator, prohibited at all times in and out of competition, on both the 2026 and 2027 Lists [5][17]. Thymosin alpha-1 is not named; thymosin-beta-4 and TB-500 are different peptides, listed in S2.3 [5][3].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Do thymosin alpha-1 and MOTS-c have similar side effects?
What are the side effects of MOTS-c in humans?
What are the most common side effects of thymosin alpha-1?
Is MOTS-c FDA approved?
Is thymosin alpha-1 FDA approved?
Can thymosin alpha-1 and MOTS-c be taken together?
References
Show all 17 referencesHide references
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Pierluigi B, D'Angelo C, Fallarino F, Moretti S, Zelante T, Bozza S, et al. Thymosin alpha1: the regulator of regulators?. Ann N Y Acad Sci. 2010;1194:1-5.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.